# Gerard Sanacora

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gerard-sanacora/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,534 |
| Field | Treatment of Major Depression |
| h-index | 86 |
| i10-index | 179 |
| Last Known Institution | Yale New Haven Hospital |
| OpenAlex ID | https://openalex.org/A5037185919 |
| ORCID iD | https://orcid.org/0000-0003-3722-8829 |
| Works | 277 |

## Researcher papers

- [Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study](https://scholariq.org/papers/efficacy-and-safety-of-intranasal-esketamine-for-the-rapid-reduction-of-symptoms/)
- [A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression](https://scholariq.org/papers/a-double-blind-randomized-placebo-controlled-dose-frequency-study-of-intravenous/)
- [Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3](https://scholariq.org/papers/efficacy-and-safety-of-esketamine-nasal-spray-plus-an-oral-antidepressant-in/)
- [Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent](https://scholariq.org/papers/esketamine-nasal-spray-for-rapid-reduction-of-major-depressive-disorder-symptoms/)
- [Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial](https://scholariq.org/papers/riluzole-augmentation-in-treatment-resistant-obsessive-compulsive-disorder-an/)
- [Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression](https://scholariq.org/papers/esketamine-nasal-spray-plus-oral-antidepressant-in-patients-with-treatment/)

## Researcher topics

- [Treatment of Major Depression](https://scholariq.org/topics/treatment-of-major-depression-2/)
- [Tryptophan and brain disorders](https://scholariq.org/topics/tryptophan-and-brain-disorders-2/)
- [Neuroscience and Neuropharmacology Research](https://scholariq.org/topics/neuroscience-and-neuropharmacology-research/)
- [Neurotransmitter Receptor Influence on Behavior](https://scholariq.org/topics/neurotransmitter-receptor-influence-on-behavior/)
- [Electroconvulsive Therapy Studies](https://scholariq.org/topics/electroconvulsive-therapy-studies/)

## Researcher university

- [Yale New Haven Hospital](https://scholariq.org/institutions/yale-new-haven-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.